Every material Form 8-K Fortress Biotech, Inc. has filed with the SEC since May 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Fortress Biotech repaid in full the remaining $15.0 million of principal on its Oaktree senior secured credit facility on September 30, 2026, plus about $435,000 of accrued interest, a $150,000 prepayment fee and other closing costs. With the repayment, the debt is satisfied, liens on company property are released, and the Oaktree Agreement terminated automatically.
Principal repaid: $15.0 million on September 30, 2026, with the facility originally a $50.0 million senior secured credit agreement dated July 25, 2024
Additional payments: about $435,000 in accrued interest and a $150,000 prepayment fee, plus other closing costs
Upon repayment, all liens securing the facility were released and the Oaktree Agreement terminated
Fortress Biotech reported second quarter 2026 net revenue of $18.7 million, up 14% from $16.4 million a year earlier, and a net loss attributable to common stockholders of $2.5 million, or $0.08 per share, compared with net income of $13.4 million, or $0.50 per share basic, in the second quarter of 2025. Operating expenses fell sharply, with research and development at $0.8 million versus $8.1 million and selling, general and administrative costs at $20.8 million versus $38.8 million, and cash and cash equivalents rose to $196.6 million as of June 30, 2026 from $79.4 million at December 31, 2025.
Net revenue was $18.7 million for the quarter, of which $17.8 million came from marketed dermatology products, compared with $16.4 million a year earlier.
Loss from operations narrowed to $10.0 million from $36.5 million, driven mainly by lower SG&A and R&D expenses.
Net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, versus net income of $13.4 million, or $0.50 per share basic, in the prior-year quarter.
Partner Crystalys Therapeutics announced a $130 million Series B financing in July 2026 for dotinurad, on which subsidiary Urica is entitled to a 3% royalty on future net sales.
Fortress Biotech reported first-quarter 2026 net income attributable to common stockholders of $108.4 million, or $2.82 per diluted share, compared with a net loss of $12.7 million a year earlier. The result was driven mainly by the sale of a Rare Pediatric Disease Priority Review Voucher by subsidiary Cyprium for $205 million gross proceeds, while net revenue rose to $16.0 million from $13.1 million.
Net revenue was $16.0 million for Q1 2026, up from $13.1 million in Q1 2025, with $15.9 million from Journey Medical's dermatology products.
Gain on sale of priority review voucher, net of expenses, was $158.9 million, according to the statement of operations.
Loss from operations narrowed to $7.7 million from $22.3 million a year earlier.
Cash and cash equivalents were $255.8 million at March 31, 2026, up from $79.4 million at December 31, 2025, and the Oaktree loan principal was reduced to $15.0 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Fortress Biotech, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →